Survival of patients with small intestine gastrointestinal stromal tumors

Authors

Abstract

Introduction: Small intestine gastrointestinal stromal tumors have a very low incidence, and few national and international publications are available about the topic.

Objective: Evaluate the overall survival of gastrointestinal stromal tumors in terms of their clinical and histopathological characteristics and their treatment.

Methods: An observational retrospective study was conducted of 131 patients with small intestine gastrointestinal stromal tumors treated at Ameijeiras Hospital from 2003 to 2019. Overall survival was evaluated with the Kaplan-Meier method. Curves were compared using Log Rank and Breslow's tests with a significance level of 0.05 and a confidence interval of 95%.

Results: A predominance was found of patients aged over 50 years, white skin color and good overall state. Mean tumor size was 11 cm. The most common metastatic sites were the liver and the peritoneum. Survival at five years was 78.3% (CI-95%:74.5; 82.1). Survival was higher in patients with tumor sizes of five cm or less, low mitotic counts, proliferative activity, localized disease, who could have their primary tumor removed, with appropriate margins, and without tumor rupture (p = 0.01). Patients achieving complete response had four times more chances than those who only obtained stabilization of the disease (p = 0.001).

Conclusions: Patients with small intestine gastrointestinal stromal tumors in Cuba exhibit optimal survival rates, similar to the ones reported internationally.

Key words: gastrointestinal stromal tumors, GIST, epidemiology, small intestine, survival.

Downloads

Download data is not yet available.

Author Biographies

Jorge Luis Soriano García, Hospital "Hermanos Ameijeiras"

Especialista de Segundo Grado en Oncología. Profesor e Investigador Titular. Doctor en Ciencias Médicas. Máster en Oncología de Precisión. Académico Titular de la ACC. Jefe de Servicio de Oncología.

Mayté Lima Pérez, Hospital Ameiejiras

Especialista de Segundo Grado en Oncología. Profesor e Investigador Auxiliar. Máster en Oncología Digestiva. Jefe de Hospitalización del Servicio de Oncología. Coordinadora de la Unidad Funcional de Tumores Digestivos.

Vilma Fleites Calvo, Hospital Ameijeiras

Especialista de Primer Grado en Oncología y MGI. Instructor

Carlos Domínguez Alvarez, Hospital Ameijeiras

Especialista de Segundo Grado en Anatomía Patológica. Profesor e Investigador Auxiliar. Servicio de Anatomía Patológica.

Masiel González Meisozo, Hospital Ameijeiras

Especialista de Primer Grado en Oncología y en MGI. Instructor.

Llipsy Teresa Fernández Santiesteban, Hospital Ameijeiras

Jefa de Servicio de Cirugía General. Profesora e Investigadora Titular. Dr. en Ciencias Médicas.

José Luis González González, Hospital Ameijeiras

Jefe de Grupo de Cirugía Hepatobiliopancreática. Profesor e Investigador Titular. Dr. en Ciencias Médicas.

Dunia Morales Morgado, Hospital Ameijeiras

Especialista de Primer Grado en Oncología y en MGI. Profesor Asistente.

Jorge Luis Hernández Castro, Hospital Ameijeiras

Licenciado en Tecnología de la Salud. Profesor Titular e Investigador Auxiliar. Doctor en Ciencias de la Salud.

Iván Ramón Concepción, Hospital Ameijeiras

Especialista de Primer Grado en Oncología y en MGI. Profesor Asistente. Máster en Ensayos Clínicos.

Noyde Batista Albuerne, Hospital Ameijeiras

Especialista de Segundo Grado en Oncología. Profesor e Investigador Auxiliar. Servicio de Oncología Clínica.

References

1. Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015;24:298-302. DOI:10.1158/1055-9965.EPI-14-1002.

2. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865-878. DOI:10.1038/nrc3143.

3. González R, Ramos R, Vallejo A, Marcilla D, Biscuola M, Martínez V, et al. Tumores del estroma gastrointestinal: breve actualización y consenso de la SEAP-SEOM sobre diagnóstico patológico y molecular. Rev Esp Patol. 2017;50(2):89-99. DOI:10.1016/j.patol.2016.12.004.

4. López Gordo S, Bettonica C, Miró M, Estremiana F, Aranda H, Farran L. Gastric and small intestine GIST: results of 156 cases in 20 years. J Gastrointest Cancer. 2021; Apr 19. Disponible en: DOI:10.1007/s12029-021-00641-x.

5. Soriano JL, Lima M, Fleites V, Domínguez C, González M, Fernández L, et al. Características clínicas y patológicas de pacientes con tumores estromales gastrointestinales en Cuba. Acta Médica. 2021;22(1):e141. Disponible en: http://www.revactamedica.sld.cu/index.php/act/article/view/141.

6. Panbude SN, Ankathi SK, Ramaswamy AT, Saklani AP. Gastrointestinal Stromal Tumor (GIST) from esophagus to anorectum - diagnosis, response evaluation and surveillance on computed tomography (CT) scan. Indian J Radiol Imaging. 2019;29(2):133-140. DOI:10.4103/ijri.IJRI_354_18.

7. Marano L, Boccardi V, Marrelli D, Roviello F. Duodenal gastrointestinal stromal tumor: From clinicopathological features to surgical outcomes. Eur J Surg Oncol. 2015; 41, 814-822. DOI:10.1016/j.ejso.2015.04.004.

8. Poveda A, Martinez V, Serrano C, Sevilla I, Lecumberri MJ, de Beveridge RD, et al. SEOM Clinical Guideline for gastrointestinal sarcomas (GIST). Clin Transl Oncol. 2016;18(12):1221-1228. DOI:10.1007/s12094-016-1579-9.

9. Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, et al. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat. 2016;48(4):1155-1166. DOI:10.4143/crt.2016.187.

10. Poveda A, García Del Muro X, López-Guerrero JA, Cubedo R, Martínez V, Romero I, and GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research). GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treat Rev. 2017; 55: 107-119. DOI:10.1016/j.ctrv.2016.11.011.

11. Landi B, Blay JY, Bonvalot S, Brasseur M, Coindre JM, Emile JF, et al. Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2019;51(9):1223-1231. DOI:10.1016/j.dld.2019.07.006.

12. Guller U, Tarantino I, Cerny T, Ulrich A, Schmied BM, Warschkow R. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis. Gastric Cancer. 2017;20(1):49-60. DOI:10.1007/s10120-015-0571-3.

13. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39(10):1411-1419. DOI:10.1016/j.humpath.2008.06.025.

14. Giuliano K, Nagarajan N, Canner J, Najafian A, Wolfgang C, Schneider E, et al. Gastric and small intestine gastrointestinal stromal tumors: Do outcomes differ? J Surg Oncol. 2017;115(3):351-357. DOI: 10.1002/jso.24514.

15. Lima M, Soriano JL, Batista N, Domínguez C, Rodríguez M, Martín M, et al. Sarcomas del estroma gastrointestinal (GIST). En: Manual de Prácticas Médicas IV Edición. Unidad Funcional de Tumores. Tomo 2. La Habana: Editorial de Ciencias Médicas, 2012. pp. 682-698.

16. Brierley JD, Gospodarowicz MK, Wittekind C. (eds). TNM Classification of Malignant Tumours, 8th ed. Oxford, United Kingdom: John Wiley & Sons, Inc. 2016.

17. Casali PG, Abecassis N, Aro HT, Bauer S, Biagini R, Bielack S, and ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv267. DOI:10.1093/annonc/mdy320.

18. Laurini JA, Blanke CD, Cooper K, Demetri GD, Dematteo RP, Fletcher CDM, et al. College of American Pathologist. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Version: GIST 4.0.1.0. June 2017[acceso: 20/4/2021]. Disponible en: https://webapps.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/GIST_12protocol_3021.pdf

19. Xing GS, Wang S, Sun YM, Yuan Z, Zhao XM, Zhou CW. Small bowel stromal tumors: different clinic pathologic and computed tomography features in various anatomic sites. PLoS One. 2015;10(12):e0144277. DOI:10.1371/journal.pone.0144277.

20. Cameron S, Beham A, Schildhaus HU. Current standard and future perspectives in the treatment of gastrointestinal stromal tumors. Digestion. 2017;95(4):262-268. DOI: 10.1159/000455835.

21. Huang Y, Zhao R, Cui Y, Wang Y, Xia L, Chen Y, et al. Effect of gastrointestinal bleeding on gastrointestinal stromal tumor patients: a retrospective cohort study. Med Sci Monit. 2018;24:363-369. DOI:10.12659/msm.908186.

22. Liu Q, Li Y, Dong M, Kong F, Dong Q. Gastrointestinal bleeding is an independent risk factor for poor prognosis in GIST patients. Biomed Res Int. 2017;2017:7152406. DOI: 10.1155/2017/7152406.

23. Scola D, Bahoura L, Copelan A, Shirkhoda A, Sokhandon F. Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging. Abdom Radiol (NY). 2017;42(5):1350-1364. DOI:10.1007/s00261-016-1025-z.

24. Nishida T, Cho H, Hirota S, Masuzawa T, Chiguchi G, Tsujinaka T, et al. Clinicopathological features and prognosis of primary gists with tumor rupture in the real world. Ann Surg Oncol. 2018;25(7):1961-1969. DOI:10.1245/s10434-018-6505-7.

25. Boonstra PA, Steeghs N, Farag S, van Coevorden F, Gelderblom H, Grunhagen DJ, et al. Surgical and medical management of small bowel gastrointestinal stromal tumors: A report of the Dutch GIST registry. Eur J Surg Oncol. 2019;45(3):410-415. DOI: 10.1016/j.ejso.2018.09.013.

26. Liu X, Qiu H, Zhang P, Feng X, Chen T, Li Y, et al. Prognostic factors of primary gastrointestinal stromal tumors: a cohort study based on high-volume centers. Chin J Cancer Res. 2018;30(1):61-71. DOI:10.21147/j.issn.1000-9604.2018.01.07.

27. Liao CH, Yeh CN, Wang SY, Fu CY, Tsai CY, Liu YY, et al. Surgical option for intestinal gastrointestinal stromal tumors--perioperative and oncological outcomes of laparoscopic surgery. Anticancer Res. 2015;35(2):1033-1040. PMID: 25667491.

28. Li J, Zhang H, Chen Z, Su K. Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a Chinese population. Int J Clin Exp Pathol. 2015;8(12):15969-76. PMID: 26884871

29. Chen K, Zhang B, Liang YL, Ji L, Xia SJ, Pan Y, et al. Laparoscopic versus open resection of small bowel gastrointestinal stromal tumors: systematic review and meta-analysis. Chin Med J (Engl). 2017;130(13):1595-1603. DOI:10.4103/0366-6999.208249.

30. Bednarski BK, Araujo DM, Yi M, Torres KE, Lazar A, Trent JC, et al. Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors. Ann Surg Oncol. 2014;21(8):2499-2505. DOI:10.1245/s10434-014-3632-7.

31. Wang J, Yin Y, Shen C, Yin X, Cai Z, Pu L, et al. Preoperative imatinib treatment in patients with locally advanced and metastatic/recurrent gastrointestinal stromal tumors: A single-center analysis. Medicine (Baltimore). 2020;99(9):e19275. DOI:10.1097/MD.0000000000019275.

32. Tirumani SH, Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH, Raut CP. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection. Eur J Surg Oncol. 2014;40(4):420-428. DOI:10.1016/j.ejso.2013.10.021.

33. Peng F, Liu Y. Gastrointestinal stromal tumors of the small intestine: progress in diagnosis and treatment research. Cancer Manag Res. 2020;12:3877-3889. DOI: 10.2147/CMAR.S238227.

34. Sandvik OM, Søreide K, Gudlaugsson E, Søreide JA. Surgery for gastrointestinal stromal tumors (GISTs) of the stomach and small bowel: short- and long-term outcomes over three decades. World J Surg. 2015;39(2):446-452. DOI:10.1007/s00268-014-2824-4.

35. Giuliano K, Ejaz A, Reames BN, Choi W, Sham J, Gage M, et al. Comparing the long-term outcomes among patients with stomach and small intestine gastrointestinal stromal tumors: An analysis of the National Cancer Database. J Surg Oncol. 2018;118(3):486-492. DOI:10.1002/jso.25172.

36. Yanagimoto Y, Takahashi T, Muguruma K, Toyokawa T, Kusanagi H, Omori T, et al. Re-appraisal of risk classifications for primary gastrointestinal stromal tumors (GISTs) after complete resection: indications for adjuvant therapy. Gastric Cancer. 2015;18(2):426-33. DOI:10.1007/s10120-014-0386-7.

37. Zhou Y, Hu W, Chen P, Abe M, Shi L, Tan SY, et al. Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(34):e7911. DOI:10.1097/MD.0000000000007911.

38. Von Mehren M, Joensuu H. Gastrointestinal Stromal Tumors. J Clin Oncol. 2018;36(2):136-143. DOI:10.1200/JCO.2017.74.9705.

Downloads

Published

2021-08-27

How to Cite

1.
Soriano García JL, Lima Pérez M, Fleites Calvo V, Domínguez Alvarez C, González Meisozo M, Fernández Santiesteban LT, et al. Survival of patients with small intestine gastrointestinal stromal tumors. Rev Cub Oncol [Internet]. 2021 Aug. 27 [cited 2025 Jul. 12];19(2). Available from: https://revoncologia.sld.cu/index.php/onc/article/view/130

Issue

Vol. 19 No. 2 (2021): mayo-agosto

Section

Artículos Originales

License

Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.

Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.

El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.